Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 4.9 Years of Treatment

被引：0
|
作者：
Lichtenstein, Gary R. [1 ]
Loftus, Edward V., Jr. [2 ]
Bloom, Stuart [3 ]
Lawendy, Nervin [4 ]
Chan, Gary [4 ]
Friedman, Gary S. [4 ]
Zhang, Haiying [4 ]
Wang, Wenjin [4 ]
Thorpe, Andrew J. [4 ]
Nduaka, Chudy I. [4 ]
Su, Chinyu [4 ]
机构：
[1] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA
[2] Mayo Clin, Rochester, MN USA
[3] Univ Coll London Hosp NHS Fdn Trust, London, England
[4] Pfizer Inc, Collegeville, PA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2018年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
571
引用
收藏
页码：S328 / S328
页数：1
相关论文
共 50 条
  • [41] SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE THIRD INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Nash, P.
    Coates, L. C.
    Kivitz, A. J.
    Mease, P. J.
    Gladman, D. D.
    Covarrubias-Cobos, A.
    Fleishaker, D.
    Wang, C.
    Kudlacz, E.
    Menon, S.
    Fallon, L.
    Hendrikx, T.
    Kanik, K. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1010 - 1011
  • [42] SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE THIRD INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Nash, P.
    Coates, L. C.
    Kivitz, A. J.
    Mease, P. J.
    Gladman, D. D.
    Covarrubias-Cobos, J. A.
    Fleishaker, D.
    Wang, C.
    Kudlacz, E.
    Menon, S.
    Fallon, L.
    Hendrikx, T.
    Kanik, K. S.
    INTERNAL MEDICINE JOURNAL, 2018, 48 : 15 - 15
  • [43] SAFETY OF LONG-TERM OZANIMOD TREATMENT FOR UP TO 4 YEARS BY AGE GROUP IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
    Siegel, Corey A.
    Rubin, David T.
    Long, Millie D.
    Danese, Silvio
    Cross, Raymond K.
    Armuzzi, Alessandro
    Dignass, Axel
    Kobayashi, Taku
    Faye, Adam S.
    Lama, Sonie
    Charles, Lorna
    Cetin, Volkan
    Petersen, AnnKatrin
    Wu, Hsiuanlin
    Wang, Dong
    Jain, Anjali
    Sabino, Joao
    GASTROENTEROLOGY, 2024, 166 (05) : S805 - S806
  • [44] Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 8
    Pope, Janet
    Keystone, Edward
    Jamal, Shahin
    Wang, Lisy
    Fallon, Lara
    Woolcott, John
    Lazariciu, Irina
    Haraoui, Boulos
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 879 - 879
  • [45] Long-term safety data for tofacitinib, an oral Janus kinase inhibitor, for the treatment for psoriasis
    Lloyd-Lavery, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 815 - 816
  • [46] Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis: Interim data from OPAL Balance, an open label, long-term extension study
    Nash, Peter
    Coates, Laura C.
    Kivitz, Alan J.
    Mease, Philip J.
    Gladman, Dafna D.
    Covarrubias-Cobos, Jose A.
    Kudlacz, Elizabeth
    Menon, Sujatha
    Kanik, Keith S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB224 - AB224
  • [47] Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
    Papp, Kim A.
    Krueger, James G.
    Feldman, Steven R.
    Langley, Richard G.
    Thaci, Diamant
    Torii, Hideshi
    Tyring, Stephen
    Wolk, Robert
    Gardner, Annie
    Mebus, Charles
    Tan, Huaming
    Luo, Yingchun
    Gupta, Pankaj
    Mallbris, Lotus
    Tatulych, Svitlana
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : 841 - 850
  • [48] Tofacitinib, an oral JAK inhibitor, in the treatment of RA: safety and clinical and radiographic efficacy in open-label, long-term extension studies over 7 years
    DeMasi, R.
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Kwok, K.
    Lazariciu, I.
    Nduaka, C.
    Connell, C.
    Wang, L.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 20 - 20
  • [49] Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE Open
    Biedermann, L.
    Dubinsky, M. C.
    Vermeire, S.
    Fellmann, M.
    Gardiner, S.
    Hur, P.
    Mundayat, R.
    Panes, J.
    Rubin, D. T.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I317 - I319
  • [50] Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
    Jürgen Wollenhaupt
    Eun-Bong Lee
    Jeffrey R. Curtis
    Joel Silverfield
    Ketti Terry
    Koshika Soma
    Chris Mojcik
    Ryan DeMasi
    Sander Strengholt
    Kenneth Kwok
    Irina Lazariciu
    Lisy Wang
    Stanley Cohen
    Arthritis Research & Therapy, 21
12345